Ask AI
ProCE Banner Activity

Interactive Treatment Decision Tool for MCL: A US Perspective

Tool

Use this Interactive Decision Support Tool to compare your choice of therapy for patients with MCL with those of 5 renowned experts from the United States.

Released: February 25, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This activity is intended for hematology/oncology physician specialists and other healthcare professionals providing care for patients with mantle cell lymphoma in the United States.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select optimal treatments for patients with treatment-naive MCL, considering expert recommendations along with available efficacy and safety evidence

  • Identify patients with MCL most likely to benefit from chemotherapy-free treatment options

  • Plan therapeutic strategies for patients with relapsed/refractory MCL based on the clinical evidence and expert guidance on current and emerging treatment options

  • Evaluate emerging evidence for novel treatment options or combinations for patients with MCL

  • Manage toxicities associated with BTK inhibitor–based therapy to support adherence, appropriate dosing, and treatment continuation for optimal patient outcomes

Disclosure

Primary Author

Brad Kahl, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Genentech, Incyte, Lilly, Merck, Pfizer, Roche.

Kami Maddocks, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Autolous, BeOne, Bristol Myers Squibb, Genentech, Genmab, Incyte, Kite/Gilead, Lilly.

Javier Munoz, MD, MS, MBA, FACP: consultant: ADC Therapeutics, Alexion, AstraZeneca, Aurobindo, Bayer, BeiGene, Celgene/Bristol Myers Squibb, Epizyme, Fosun/Kite, Genentech/Roche, Genmab, Genzyme, Gilead/Kite, Janssen, Karyopharm, Kyowa, Lilly, MEI, MorphoSys/Incyte, Novartis, Pfizer, Pharmacyclics/AbbVie, Seattle Genetics, TG Therapeutics, Verastem; research funding: Bayer, BeiGene, Celgene, E.R. Squibb & Sons, Genentech, Gilead/Kite, Incyte, Janssen, Merck, Millennium, Novartis, Pharmacyclics, Portola, Seattle Genetics; honoraria: Aptitude Health, Curio, OncView, Targeted Oncology.

Tycel J. Phillips, MD: advisory board: AbbVie, ADCT, BeiGene, Celgene/Bristol Myers Squibb, Genentech, Genmab, Lilly, Merck, Pharmacyclics, Seattle Genetics/Pfizer, Xencor; researcher: AbbVie, ADC, Bristol Myers Squibb, Genentech, Sobi; consultant: AbbVie, AstraZeneca, Bristol Myers Squibb, Caribou, Genentech, Gilead/Kite, Incyte, Ipsen, Janssen, Johnson & Johnson, Pfizer, Xencor.

Julie M. Vose, MD, MBA: consultant/advisor/speaker: AbbVie, Ascentage, BeOne, Genentech, GenMab, Kyowa Kirin.